(Q42113451)

English

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

scientific article published on 21 February 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma (English)

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1 reference

ChEBI release 2020-05-28

object named as

Pol Specenier

10

0 references

object named as

Olivier Chinot

6

0 references

19

object named as

Wolfgang Wick

1 reference

Europe PubMed Central

16 October 2017

PMC publication ID

9

object named as

David Capper

1 reference

Europe PubMed Central

16 October 2017

PMC publication ID

Alba A. Brandes

1

object named as

Alba A Brandes

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

author name string

Antoine F Carpentier

2

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Santosh Kesari

3

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Juan M Sepulveda-Sanchez

4

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Helen R Wheeler

5

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Lawrence Cher

7

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Joachim P Steinbach

8

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Jordi Rodon

11

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Ann Cleverly

12

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Claire Smith

13

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Ivelina Gueorguieva

14

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Colin Miles

15

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Susan C Guba

16

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Durisala Desaiah

17

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Michael M Lahn

18

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

21 February 2016

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

18

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

8

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1146-1156

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

TGF-beta, neuronal stem cells and glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

Macrophage-derived chemokine (MDC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

29 May 2018

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Randomization by minimization for unbalanced treatment allocation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Benton Controlled Oral Word Association Test: reliability and updated norms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Molecular determinants of glioma cell migration and invasion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4933481

17 August 2018

Repetition priming with nonverbal stimuli in patients with dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOW009

21 January 2018

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOW009

21 January 2018

Identifiers

10.1093/NEUONC/NOW009

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42113451&oldid=1933836840"